Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04484142 · ClinicalTrials.gov registry record · Phase 2
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT04484142 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 137 participants.
The verdict
NCT04484142, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
Interventions
- DRUG DS-1062a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2026-02-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04484142
The ClinicalTrials.gov registry entry for NCT04484142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DS-1062a is the first listed.
NCT04484142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04484142 about?
NCT04484142 is a clinical study titled "Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)". This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung cancer (NSCLC) with known actionable genomic alterations.
What is the current status of trial NCT04484142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2021-03-30. Estimated completion is 2026-02-04.
What interventions are being tested in trial NCT04484142?
The interventions under investigation include: DS-1062a (DRUG).
Who is sponsoring clinical trial NCT04484142?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.